Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia by Hornung, Roman et al.
1SCIENTIFIC RepoRtS |  (2018) 8:11293  | DOI:10.1038/s41598-018-29593-2
www.nature.com/scientificreports
Mediation analysis reveals common 
mechanisms of RUNX1 point 
mutations and RUNX1/RUNX1T1 
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Alterations of RUNX1 in acute myeloid leukemia (AML) are associated with either a more favorable 
outcome in the case of the RUNX1/RUNX1T1 fusion or unfavorable prognosis in the case of point 
mutations. In this project we aimed to identify genes responsible for the observed differences in 
outcome that are common to both RUNX1 alterations. Analyzing four AML gene expression data sets 
(n = 1514), a total of 80 patients with RUNX1/RUNX1T1 and 156 patients with point mutations in RUNX1 
were compared. Using the statistical tool of mediation analysis we identified the genes CD109, HOPX, 
and KIAA0125 as candidates for mediator genes. In an analysis of an independent validation cohort, 
KIAA0125 again showed a significant influence with respect to the impact of the RUNX1/RUNX1T1 
fusion. While there were no significant results for the other two genes in this smaller validation 
cohort, the observed relations linked with mediation effects (i.e., those between alterations, gene 
expression and survival) were almost without exception as strong as in the main analysis. Our analysis 
demonstrates that mediation analysis is a powerful tool in the identification of regulative networks in 
AML subgroups and could be further used to characterize the influence of genetic alterations.
Alterations of the Runt-related transcription factor (RUNX1) have been observed to strongly influence the out-
come of patients with acute myeloid leukemia (AML)1. In the case of missense or frameshift mutations, RUNX1 
has a negative effect, that is, the affected patients have a considerably shorter survival compared to those without 
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these mutations. In contrast, the RUNX1/RUNX1T1 fusion, in the following denoted as t(8; 21), is associated with 
a more favorable outcome in comparison to patients without fusions.
The observed influences of mutations and fusions on survival are not fully direct, but can be assumed to be 
in part due to transcriptional deregulation of other genes resulting from alterations of the transcription factor 
RUNX1. The latter means that the considered alterations have an effect on the expression of these genes and, 
at the same time, they themselves have an effect on survival independent of the alteration. However, it is not 
known which genes play an important role here. We were particularly interested in identifying genes with altered 
expression that contribute to the strong effect of RUNX1 mutations and fusions on survival outcome. Such genes 
cannot be identified through standard differential expression analyses (e.g., using the limma approach2) by sim-
ply comparing expression levels in the altered group to those in the non-altered group, because this approach is 
not appropriate to identify genes with an effect on survival. On the other hand, identifying genes associated with 
survival (e.g., using Cox regression models) does not allow finding genes whose expression levels are affected by 
the considered alteration. We aim at identifying genes that both are affected by alterations and affect the survival 
outcome. Such questions can be addressed by “mediation analysis” methods that allow testing whether variables 
(e.g. genes) are affected by an exposure and, at the same time, have an influence on the outcome. While statistical 
procedures for mediation analyses are widely applied in general, they have not often been used in gene expres-
sion analyses. To our knowledge, there exists only one publication in this context: Huang et al.3 used a mediation 
analysis procedure to identify gene expression variables that help explain the influence of micro-RNA expression 
variables on survival. In general, mediation analyses are concerned with measuring and testing indirect effects 
of risk factors of interest on target variables through particular mediator variables. Such an analysis is well suited 
for the main goal of our approach - identifying genes through which RUNX1 mutations and fusions influence the 
outcome. Given the fact that large gene expression and sequencing data from the same patients are necessary for 
such an analysis, it is not surprising that mediation analysis has not been applied in this context to date.
After identifying mediator genes with an appropriate mediation analysis approach, we performed several 
descriptive analyses in order to gain further insights into the role of these genes and on their interplay. In an 
analysis of an independent validation cohort, one of the three identified genes was again a significant mediator 
gene with respect to the impact of the RUNX1/RUNX1T1 fusion. While there were no significant results for 
the other two genes in this smaller validation cohort, the observed relations linked with mediation effects (i.e., 
those between alterations, gene expression and survival) were almost without exception as strong as in the main 
analysis.
Methods
Using the terminology of mediation analysis, in the following, the influential genes will be termed “mediator 
genes” or “mediators”. The mutation and the fusion will be called the exposure.
Patient cohorts and gene expression data. Four data sets were included in our main analysis, to which 
we will refer to as AMLCG Cohort 1, HOVON, TCGA and AMLCG Cohort 2. The AMLCG Cohort 1 consisted 
of 488 patients treated on the AMLCG-1999 trial of the German AML Cooperative Group (GSE37642)4–6. The 
HOVON cohort had 462 patients treated on various trials of the Dutch Haemato-Oncology Cooperative Study 
Group (HOVON). Clinical and gene expression data are publicly available (GSE14468)7,8. The TCGA cohort 
was composed of 179 AML samples published by The Cancer Genome Atlas Project9. For the TCGA cohort, we 
used the corrected clinical data published with Data Release 9.0 on October 24, 2017. AMLCG Cohort 2 had 260 
patients treated on the AMLCG-2008 and the AMLCG-1999 trials10. The gene expression data is publicly avail-
able (GSE106291). After excluding patients with missing data and non-intensive induction treatment (TCGA), 
the following case numbers were obtained: n = 469 (AMLCG Cohort 1), n = 461 (HOVON), n = 100 (TCGA), 
and n = 252 (AMLCG Cohort 2) (Supplementary Fig. S1). For all variables with missing values, missingness 
can be assumed to be independent from the missing values themselves and also to be independent from the 
values of other variables in the data sets. Each data set contains several ten thousand gene expression variables, 
either measured by Affymetrix Arrays (AMLCG Cohort 1 and HOVON) or RNA sequencing (RNAseq, TCGA 
and AMLCG Cohort 2). The microarray cohorts were preprocessed with the RMA (Robust Multichip Average) 
method11, and the raw counts created by RNASeq were preprocessed using the R-package DESeq212. All study 
protocols were in accordance with the Declaration of Helsinki and were approved by the institutional review 
boards. Informed consent was obtained from all subjects and all experiments were performed in accordance with 
relevant guidelines and regulations. The analysis was approved by the ethics committee of the medical faculty of 
the University of Munich.
In the following, the suffixes “+” and “−” will be added to “RUNX1” and “t(8; 21)” to indicate the presence 
and absence of RUNX1 point mutations and the RUNX1/RUNX1T1 fusion, respectively. For better readability, the 
suffix “+” is omitted in cases where there is no risk of confusion. For each data set, the survival information, that 
is, survival and censoring times, is available. Information on the number of observations per data set with infor-
mation on fusions, mutations, and both fusions and mutations, is given in Fig. 1. For AMLCG Cohort 2 genes that 
were not expressed in more than 90% of samples were excluded from the analysis.
We also used an independent validation cohort13. From this validation cohort, we were able to use the data from 
232 patients. Information on overall survival as well as mutation and fusion status, sex and age was available for 
each patient. As gene expression values, we used reads per kilobase per million reads (RPKM) values for these data.
Analysis outline. The following three comparisons were performed for the selection of influential genes (for 
details, see further down): (1) patients with and without fusion (t(8; 21)+ vs. t(8; 21)−), (2) patients with and with-
out mutation (RUNX1+ vs. RUNX1−), (3) patients with fusion only and patients with mutation only (t(8; 21)++ vs. 
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RUNX1++). See the next two subsections for a detailed description of the procedures performed for the selection 
of influential genes.
After determining a set of influential genes for each comparison, we investigated these genes further. For sets 
resulting from comparisons 1 and 2, we produced heatmaps in order to obtain insights into the relationships 
between the genes in these sets. Because the set of genes found to be mediators with respect to the survival differ-
ences between t(8; 21)+ and RUNX1+ (comparison 3) was much smaller than for the other two comparisons and 
because this set is the most interesting of the three sets as it contains genes relevant to both mutations and fusions, 
we investigated this set more thoroughly by estimating partial correlations between these genes. Moreover, we 
produced Kaplan-Meier curves for these genes comparing high and low levels (where the median is used as 
cutoff) of gene expression not only for the whole patient collectives, but also separately for patients without muta-
tions or fusion, for patients with mutations only, and for patients with fusions only. In order to obtain insights into 
the biological determinants that drive the differences in outcome between RUNX1+ and t(8; 21)+, we performed 
an over-representation analysis14. Lastly, in order to affirm the relevance of the set of genes found to be mediators 
with respect to the survival differences between t(8; 21)+ and RUNX1+ (comparison 3) we analyzed the inde-
pendent validation cohort.
In all analyses, the primary outcome was overall survival. Unless otherwise stated, p values smaller than 0.05 
are considered significant (α = 0.05).
Definition of mediator effects and testing procedure. Let E be the exposure (i.e., mutation or fusion) 
and S the survival outcome, which is influenced by E. Then a mediation effect for gene M means the following: 
the relationship between the survival outcome S and the exposure E is partially or totally due to gene M which is 
taking the role of a mediator15, see Fig. 2. To make the concept of mediation more clear, consider the following 
fictional example: A low socioeconomic status might be observed to lead to a higher risk of death. Here, the low 
socioeconomic status would take the role of the exposure. A potential mediator in this context could be ‘nutrition’: 
A low socioeconomic status might be associated with a less balanced nutrition which in turn leads to higher risk 
of death. By identifying mediator genes we attempt to explain the strong influence mutations and fusions have 
on the survival outcome. We consider only those mediator effects which support, not inhibit, the observed influ-
ence of the exposure on the survival outcome. For example, as RUNX1 mutations lead to shorter survival times, 


















d   AMLCG Cohort 2 (n = 252)
Figure 1. Venn diagrams of case numbers in the data sets. Panels a, b, c, and d show the case numbers available 
for AMLCG Cohort 1, HOVON, TCGA, and AMLCG Cohort 2, respectively.
www.nature.com/scientificreports/
4SCIENTIFIC RepoRtS |  (2018) 8:11293  | DOI:10.1038/s41598-018-29593-2
times, that is, genes that are more expressed in RUNX1+ patients and negatively associated with survival or genes 
that are less expressed in RUNX1+ patients and positively associated with survival. Other mediation effects are 
ignored in our analysis, since they do not contribute to capturing the survival differences between RUNX1+ 
and RUNX1−. We used the testing framework introduced by Lange and Hansen16, adjusting for the (possibly) 
confounding variables sex, age, and cytogenetics. See the Supplementary Information for details on the followed 
procedure. We implemented our analysis using our new R package ‘survmediation’ (available from GitHub, link: 
https://github.com/RomanHornung/survmediation) which is based on the original code by Lange and Hansen.
Pre-selection of promising genes and adjustment for multiple testing. In identifying the relevant 
genes through testing each gene separately, we faced a multiple testing problem. An adjustment for multiple 
testing, for example by the Benjamini-Hochberg procedure, for all of the many thousands of tests necessary for 
each of the three comparisons would have resulted in a very small number of significant genes. Moreover, using 
the combined data of all four data sets for testing would have resulted in a suboptimal performance of the testing 
procedure for the following reason: the data behave quite differently in the individual data sets, because of batch 
effects17, in particular, because the data sets have different data types.
As a solution to these problems, we pre-selected promising genes using one data set, termed “pre-selection 
data set”, and validated this reduced list of genes in another data set, termed “validation data set”. Adjusting for 
multiple testing was only performed in the “validation data set”. First, for each of the three comparisons succes-
sively, using the corresponding pre-selection data set we pre-selected the genes that had a p value smaller than 
0.05. This pre-selection led to a comparably short list of genes that was expected to contain a high density of true 
influential genes. Second, as already noted above, these promising genes were tested again – this time using the 
validation data set. The p values from these tests were then adjusted by the Benjamini-Hochberg procedure. By 
pre-selecting promising genes using independent data sets as described above, the problem of multiple testing 
was mitigated in the validation data sets, because the number of tests was reduced strongly.
For two of the three comparisons, we used a concatenation of the two data sets AMLCG Cohort 2 and TCGA 
in the pre-selection. ComBat18 was used to remove batch effects between AMLCG Cohort 2 and TCGA in the 
concatenated data set denoted as “AMLCG Cohort 2 with TCGA” in the following. See Fig. 3 for an overview on 
the data sets used for the pre-selection and validation for each of the three comparisons and the number of genes 
selected for each comparison in the pre-selection and validation, respectively. For details on the processing of the 
pre-selection data sets and the validation data sets, see the Supplementary Information.
Distinction of mediation analysis from differential expression analysis. Many of the genes iden-
tified in this paper as candidates for mediator genes with respect to the influence of RUNX1 and t(8; 21) on the 
outcome have been identified before as being differentially expressed with respect to RUNX1+ vs. RUNX1− 19. In 
this subsection, we demonstrate that, while differential expression is a prerequisite for mediation activity, genes 
that are differentially expressed are by no means necessarily mediator genes.
If the expression of a gene is influenced by the exposure (e.g. RUNX1+ vs. RUNX1−), the gene is said to be 
differentially expressed with respect to the exposure. However, a gene that is differentially expressed does not nec-
essarily have an influence on the patients’ outcome. By contrast, mediation activity of a gene requires the follow-
ing two conditions to be fulfilled: (1) The gene is differentially expressed with respect to the exposure, that is, its 
expression is influenced by the exposure; (2) The gene’s expression has an effect on the outcome after adjusting for 
(or ‘independent of ’) the influence of the exposure on the outcome. The latter requirement that the gene should 
be influential after adjusting for the influence of the exposure on the outcome is a crucial requirement for the 
existence of mediation activity: If, after adjusting for the influence of the exposure on the outcome, the gene had 
no influence on the outcome, this would mean that the observed influence of the gene on the outcome would be 
merely due to the influence of the exposure on the gene (perfect confounding). In this case, the gene itself would 
have no actual influence on the outcome. Thus, it would not help to explain the influence of the exposure on the 
outcome, but it would merely be differentially expressed.
We performed the following analysis to demonstrate that it can be expected that the majority of differentially 
expressed genes show no mediator actitivity. First, we applied linear models using moderated t-statistics20 as 
implemented in the BioConductor package limma2 to AMLCG Cohort 1 to select genes differently expressed 







Figure 2. Illustration of mediator effect. The direct effect of E on S is depicted in grey and the mediator effect 
also known as indirect effect is depicted in green.
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the Benjamini-Hochberg procedure. Due to the high number of genes found differentially expressed at the 5% 
significance level and in order to increase confidence in the relevance of the identified genes, in this analysis, we 
considered genes with p values smaller than 0.01 as significant (α = 0.01), resulting in 1146 significantly differ-
entially expressed genes. Subsequently, for each of these 1146 genes we performed two Cox regressions: (a) using 
only the gene as covariate for survival and (b) using the gene plus the exposure variable RUNX1+ vs. RUNX1− as 
covariates for survival. For each of these regressions, we recorded the p value obtained for the regression coeffi-
cient of that gene. Again using the Benjamini-Hochberg procedure we corrected these p values, for both types of 
regressions (a) and (b), separately.
Figure 4 shows the distributions of the p values obtained for the regressions (a) and (b), respectively, as well 
as the p values obtained for these genes in the differential expression analysis (which are all smaller than 0.01 due 
to the selection described above). We make two main observations: (1) The majority of differentially expressed 
genes are not significantly associated with survival, neither when considered alone (regressions (a)) nor when 
considered in combination with the exposure (regressions (b)); (2) When considered as covariates in combination 
with the exposure (regressions (b)), much less genes are significantly associated with survival compared to when 
the genes are considered as covariates alone (regressions (a)). Observation (1) illustrates the fact described above: 
Differentially expressed genes do not necessarily affect the patients’ outcome. Observation (2) demonstrates that, 
Figure 3. Workflow of mediator selection.
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when investigating the influence of genes on the outcome, it is crucial to adjust for the influence of the exposure. 
If this adjustment is not performed, many genes will significantly influence the survival outcome although they 
do not have a genuine influence on the outcome; in these cases, the significant influence of the gene’s expression 
on survival is likely due to the gene’s expression values being merely correlated with the outcome, because the 
exposure has an influence on both the gene’s expression as well as on the outcome. As already described above, 
only genes that are influenced by the exposure and at the same time influence the outcome when adjusted for the 
influence of the exposure can help explain the strong influence of the exposure on the outcome, that is, can be 
considered as candidates for mediator genes.
In the main mediation analysis described in the next section we identified three genes as candidates for medi-
ators with respect to the observed differences in outcome of patients with RUNX1 point mutations and those 
with RUNX1/RUNX1T1 fusions. These three genes were all among the differentially expressed genes identified in 
this subsection. Moreover, their influences were significant in both Cox regressions (a) and (b) described above 
(results not shown). This demonstrates that genes that show mediator activity are both influenced by the exposure 
and at the same time have an influence on the outcome, even after adjusting for the influence of the exposure on 
the outcome. Separately investigating two regression models, one measuring the influence of the exposure on the 
mediator and one measuring the influence of mediator and exposure on the outcome as performed in this sub-
section corresponds to the traditional approach to mediation analysis. This approach has, however, been shown to 
be flawed in many cases21. Modern analyses mainly use approaches based on the so-called counterfactual frame-
work21. The approach by Lange and Hansen used in our analyses is as well based on this framework.
Availability of data and materials. The TCGA data is publicly available in processed form through 
https://cancergenome.nih.gov/. The HOVON and AMLCG data sets are available through the Gene Expression 
Omnibus (GEO) website (GSE37642, GSE14468, GSE106291).
The complete R code written to perform and evaluate the analyses is available in the Electronix Appendix to 
this article.
Results
Overall influence of RUNX1 mutations and t(8; 21) on survival. RUNX1 mutations (n = 123) and 
fusions (n = 75) were almost mutually exclusive in all three data sets which had information on RUNX1 and t(8; 21). 
This is in line with previous analyses showing that these alterations define specific genetic groups in AML22,23. 
Figure 5 shows the observed influence of RUNX1 mutations and fusions on the survival function. Clearly, patients 
with RUNX1 mutations have a very unfavorable outcome, while t(8; 21) positive patients have a more favorable 
prognosis.
Selection of influential genes. For the comparison t(8; 21)+ vs. t(8; 21)−, 665 (3.82%) genes had p values 
smaller than 0.05 in the pre-selection (see Fig. 3). Testing these 665 genes using the corresponding validation data 
set, 68 genes were still significant after adjustment for multiple testing (Supplementary Table S1).
For the comparison RUNX1+ vs. RUNX1−, 258 (1.87%) genes were pre-selected (see Fig. 3). After testing 
these pre-selected genes using the validation data set and adjusting for multiple testing, 12 genes remained signif-
icant (Supplementary Table S2).
A total of 301 (2.18%) genes were pre-selected for the last comparison t(8; 21)++ vs. RUNX1++ (see Fig. 3 
and Supplementary Information). When testing these genes using the validation data set, no significant results 
were obtained after adjustment for multiple testing. Thus, in this direct comparison, we could not identify 
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Figure 4. Histograms of p values from differentially expressed genes in Cox regression analysis. The left 
and middle panels show the Benjamini-Hochberg adjusted p values of the influences of the genes in Cox 
regressions performed separately for each gene that used as covariates the corresponding genes (panel a) or the 
corresponding genes as well as the exposure RUNX1+ vs. RUNX1− (panel b). Panel c shows the Benjamini-
Hochberg adjusted p values of the genes found to be differentially expressed at the 1% significance level from the 
differential expressions analysis performed using limma.
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of identifying such genes is to compare Supplementary Tables S1 and S2. Genes occurring in both tables are 
associated with both t(8; 21) and RUNX1 and are therefore also responsible for the differing survival behav-
iors between patients with t(8; 21) and RUNX1. The following three genes are present in both tables: CD109, 
KIAA0125, and HOPX. The fact that no genes were identified in the t(8; 21)++ vs. RUNX1++ comparison 
can probably be attributed to the small sample size. Note that one of the three genes that occur in both tables, 
namely HOPX, is regulated by RUNX1 (see the ORegAnno Database24). Given that we could not identify any 
significant candidates for mediator genes in the direct comparison t(8; 21)++ vs. RUNX1++, we decided to 
perform a further, more robust, mediation analysis for this direct comparison. In this analysis, we considered 
only genes used in the LSC17 prognostic score25, because these genes are known to have prognostic relevance 
and might thus be promising candidates for mediator genes for t(8; 21)++ vs. RUNX1++. This additional anal-
ysis is more robust than the main analysis presented above, because, due to the much smaller number of genes 
considered in this additional analysis, the effect of the adjustment for multiple testing is much less severe. In this 
analysis, the following three genes were significant after adjustment for multiple testing: GPR56, KIAA0125, and 
NGFRAP1. Note that KIAA0125 was also in the previous analysis among the three genes identified as candidates 
for mediation activity with respect to t(8; 21)++ vs. RUNX1++. The other two of the three genes discussed 
before, CD109 and HOPX, were not considered in the current analysis, because these two genes are not among 
the genes featured in LSC17 that were studied here. Note that in performing this analysis we have used the same 
data a second time, which is why we attribute a lower priority to the two genes GPR56 and NGFRAP1 which were 
identified only in this analysis than to the three genes identified in the main analysis. See the Supplementary 
Information for details on the design and the results of this analysis. In the subsection ‘Distinction of mediation 
analysis from differential expression analysis’ we discussed the conceptual differences between mediation analysis 
and differential expression analysis using, for example, limma. In order to illustrate that, while mediator genes 
are differentially expressed, differentially expressed gene are not (necessarily) mediator genes, we performed 
an additional analysis: We applied limma to select differentially expressed genes, using AMLCG Cohort 2 with 
TCGA as pre-selection data set (p value threshold for pre-selection: 0.05) and AMLCG Cohort 1 as validation 
data set, again adjusting the p values obtained on the validation data set using the Benjamini-Hochberg proce-
dure. Adjusting for sex, age, and cytogenetics as in the mediation analysis we obtained the following results: 3078 
(22.29%) genes were pre-selected and 1317 (9.54% from all 13808 genes tested) of these 3078 genes were signifi-
cant after Benjamini-Hochberg adjustment in the validation analysis (Supplementary Information). All five can-
didate genes CD109, HOPX, KIAA0125, GPR56, and NGFRAP1 were among these 1317 genes selected by limma. 
This demonstrates that only a very small proportion of differentially expressed genes identified by limma can be 
expected to be mediator genes. This illustrates that limma is not suitable for detecting mediator genes. Note that 
mediation activity of a gene means that this gene is differentially expressed and - at the same time - that its expres-
sion influences the outcome independently from the influence the exposure (e.g., t(8; 21)++ vs. RUNX1++) has 
on the expression of that gene.
Descriptive analyses of the selected genes. First, in order to quantify the prognostic relevance of the 
three genes selected in both comparisons, t(8; 21)+ vs. t(8; 21)− and RUNX1+ vs. RUNX1−, we performed 
a univariate Cox proportional hazards regression analysis for each gene using the validation data set AMLCG 
Cohort 1. Before applying Cox regression, we centered and scaled the log2 transformed expression values of the 
three genes to have mean zero and variance one in order to make comparisons of the values of the hazard ratio 
possible. The results of the Cox regression are shown in Supplementary Table S4. The values of the hazard ratio 
and that of Harrell’s concordance index are quite similar across genes, with CD109 having the highest values. 
While the values of the concordance index (range: 0.552–0.587) would be considered small in the context of 
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Figure 5. Survival differences between patients with and without RUNX1 and t(8; 21), respectively. Panel a 
shows two Kaplan Meier curves, separately for patients with RUNX1+ and RUNX1−, panel b two Kaplan Meier 
curves, separately for patients with t(8; 21)+ and t(8; 21)−, and panel c two Kaplan Meier curves, separately for 
patients with RUNX1++ and t(8; 21)++ treated within the AMLCG Cohort 1. Censorings are indicated as plus 
signs. The p values are the results of log-rank tests used to test for survival differences between the two groups 
associated with the respective Kaplan Meier curves.
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multivariable predictive models, but consider the predictive performance of individual genes. More than 98% 
of the concordance indices obtained for the other 17,384 gene expression variables in AMLCG Cohort 1 were 
smaller than the smallest of the concordance indices obtained for the three genes considered here.
Next, in order to detect possible subgroups among the genes selected for comparisons t(8; 21)+ vs. t(8; 21)− 
and RUNX1+ vs. RUNX1−, respectively, we created heatmaps for both of these two comparisons, clustering the 
genes using the agglomerative hierarchical clustering approach. For the genes selected from comparison t(8; 
21)+ vs. t(8; 21)−, we created a heatmap for both HOVON and AMLCG Cohort 1, because these data sets were 
used in the pre-selection and validation for this comparison (see Fig. 3). For AMLCG Cohort 1, we only consid-
ered samples with both t(8; 21)− and RUNX1−. For the HOVON cohort, we considered the samples with t(8; 
21)− (the samples had no information on the mutation status in this data set). Supplementary Figs S2 and S3 
show the heatmaps obtained for the data sets HOVON and AMLCG Cohort 1, respectively. For both data sets, 
the genes cluster into two quite distinct groups of similar size. The k-means clustering method with k = 2 found 
similar clusters as agglomerative hierarchical clustering (with complete linkage and Euclidean distance) in both 
data sets (adjusted Rand index: HOVON: 0.83, AMLCG Cohort 1: 0.72). Thus, the two clusters seem to be quite 
stable within the two data sets. However, the two largest clusters found using hierarchical clustering differ to a 
stronger degree between the two data sets (adjusted Rand index: 0.27) than do the clusterings generated with the 
two clustering methods within the same data sets. The clusterings obtained for the two data sets differ also with 
respect to the cluster memberships of the three genes selected in both comparisons (t(8; 21)+ vs. t(8; 21)− and 
RUNX1+ vs. RUNX1−): the gene HOPX is in the same cluster as CD109 for the HOVON data set and in the same 
cluster as KIAA0125 for AMLCG Cohort 1.
In the case of the genes selected for comparison RUNX1+ vs. RUNX1−, the combined data set AMLCG 
Cohort 2 with TCGA and AMLCG Cohort 1 were used to create heatmaps (see Supplementary Figs S4 and S5). 
These two data sets were used for pre-selection and validation, respectively, for this comparison (Fig. 3). For both 
data sets only the samples with both t(8; 21)− and RUNX1− were used. In the case of AMLCG Cohort 2 with 
TCGA, there are again two large clusters, where the three genes selected in both comparisons are contained in the 
same cluster. In the case of AMLCG Cohort 1, however, the 12 considered genes seem to cluster into three distinct 
groups. Again, as in Supplementary Fig. S3, HOPX and KIAA0125 are in the same cluster, whereas CD109 is in a 
different cluster, which is, however, not surprising since the results shown in Supplementary Figs S3 and S5 were 
obtained using the same data set.
Figure 6 shows the expression values of CD109, KIAA0125, and HOPX (data sets AMLCG Cohort 1 and 
AMLCG Cohort 2 with TCGA) separated by whether mutations, fusions, or neither of these two were present in 
the samples. Quite apparently, RUNX1 mutations are associated with higher and the t(8; 21) with lower expression 
levels for all three genes. For each of these genes, higher expression values are associated with a poorer prognosis.
Figure 7 shows the partial correlations between the expression levels of these three genes for each of the three 
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Figure 6. Log2 expression values for the three genes selected as mediators both for the RUNX1+ vs. RUNX1− 
comparison and the t(8; 21)+ vs. t(8; 21)− comparison. Log2 expression values in AMLCG Cohort 1 (panel a) and 
AMLCG Cohort 2 with TCGA (panel b) for the three genes that appear in both, Supplementary Tables S1 and S2, 
separated by whether only mutations (RUNX1+), only fusion (t(8; 21)+) or neither of these two (RUNX1− and 
t(8; 21)−) are present in the respective patients. The p values are the results of Wilcoxon tests. For each gene, we 
tested ‘RUNX1+’ against ‘RUNX1− and t(8; 21)−’ and ‘t(8; 21)+’ against ‘RUNX1− and t(8; 21)−’.
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the partial correlation between these genes is stronger for AMLCG Cohort 2 with TCGA and AMLCG Cohort 
1 than for HOVON. Note that HOVON was also the only data set for which KIAA0125 and HOPX were not in 
the same cluster. Moreover, there is a partial correlation larger than 0.2 between KIAA0125 and CD109 for both 
AMLCG Cohort 1 and HOVON and a partial correlation larger than 0.2 for AMLCG Cohort 2 with TCGA.
Interestingly, the prognostic effect of patients with high and low expression values of the three mediator genes 
was not limited to patients with RUNX1 mutations or fusions. Figure 8 shows Kaplan Meier curves comparing 
the survival outcomes of all patients with high and all patients with low expression values of the three genes 
selected for both comparison “RUNX1+ vs. RUNX1−” and “t(8; 21)+ vs. t(8; 21)−” (AMLCG Cohort 1 data 
set). Moreover, Supplementary Fig. S6 shows corresponding Kaplan Meier curves for the subgroup of patients 
without RUNX1 mutations or fusions. These Kaplan Meier curves suggest that these genes also influence survival 
for patients without RUNX1 mutations or the t(8; 21) fusion.
Over-representation analysis. Above we have determined lists of genes that contribute to the strong 
observed influences of RUNX1 mutations and fusions on survival. It would be desirable to additionally identify 
mechanisms for the differences in outcome between RUNX1+ and t(8; 21)+ that are better interpretable than are 
lists of genes. We therefore performed an over-representation analysis with the aim of identifying specific anno-
tation sets associated with the outcome difference of RUNX1 mutations and fusions.
We identified candidate drivers separately for the comparisons RUNX1+ vs. RUNX1− and t(8; 21)+ vs. t(8; 
21)−. For each of these two comparisons we considered those genes in the over-representation analysis that 
were significant to the significance level 0.10 on the validation data sets before adjustment for multiple testing. 
The reason why we chose 0.10 as significance level here instead of 0.05 as in the rest of the paper, was that by 
choosing a high significance level more candidates for potential drivers can be expected to be obtained. Note 
that while increasing the significance level would be considered as fishing for significance in other situations, this 
is not problematic in the analysis at hand, because, as explained below, the considered analysis flow is of a mere 
explorative nature. This selection resulted in 62 genes for the comparison RUNX1+ vs. RUNX1− and 252 genes 
for the comparison t(8; 21)+ vs. t(8; 21)−, respectively (Supplementary Information). These two lists were ana-
lyzed with ConsensusPathDB14. Subsequently, we determined those drivers from the identified annotation sets 
that were common to both lists. We identified the gene ontology-based sets: GO:0010876 lipid localization and 
GO:0005548 phospholipid transporter activity as common and enriched in both comparisons.
Note that these drivers should be interpreted with caution. They can merely be considered in an informal 
discussion on potential drivers for the large differences in outcome between patients with RUNX1+ and those 
with t(8; 21)+. The reason for this limited interpretability of the identified drivers is the fact that the considered 
analysis flow is of explorative nature. This analysis flow did not allow us to perform statistical testing in the strict 
sense, that is, the identified drivers cannot be declared as “significant”. As they are the result of a descriptive anal-
ysis, their relevance must be validated in future studies before drawing valid conclusions from these findings.
Validation of the candidate mediator genes in an independent cohort. Using the validation 
cohort described in the subsection ‘Patient cohorts and gene expression data’, we re-performed the mediation 
analysis for the selected genes CD109, KIAA0125, and HOPX. From the 232 patients available, 33 had a RUNX1 
mutation and five a RUNX1/RUNX1T1 fusion. Mutations and fusions were mutually exclusive.
In order to test for mediation activity of the three genes, again we employed the testing framework introduced 
by Lange and Hansen using the same setup as in the main analysis, adjusting for sex and age. Given the compa-
rably small sample size of the validation cohort, we only considered the comparisons RUNX1+ vs. RUNX1− 
and t(8; 21)+ vs. t(8; 21)−, not the comparison t(8; 21)++ vs. RUNX1++; for the latter comparison only 38 
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Figure 7. Partial correlations between the expression levels of the three genes selected both for RUNX1+ 
vs. RUNX1− and t(8; 21)+ vs. t(8; 21)− estimated using AMLCG Cohort 2 with TCGA (panel a), AMLCG 
Cohort 1 (panel b), and HOVON (panel c), respectively. Only partial correlations larger than 0.2 are shown. 
The strengths of the partial correlations are reflected by the widths of the lines. In the case of the data sets 
AMCLG Cohort 2 with TCGA and AMLCG Cohort 1 all patients with RUNX1− and at the same time t(8; 21)− 
were used. In the HOVON data set all patients with t(8; 21)− were used (the information on the presence of 
RUNX1+ was not given for this data set).
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fact that in the main analysis we were not able to find any significant genes in the direct comparison t(8; 21)++ 
vs. RUNX1++.
In the comparison RUNX1+ vs. RUNX1− only the gene KIAA0125 was significant (p = 0.014), whereas the 
genes CD109 (p = 0.076) and HOPX (p = 0.096) were merely ‘weakly significant’ (i.e., significant at the level 
α = 0.10). In the comparison t(8; 21)+ vs. t(8; 21)− none of the three genes were significant or ‘weakly significant’ 
(KIAA0125: p = 0.121, CD109: p = 0.351, HOPX: p = 0.176). Note, however, that only five patients with t(8; 21)+ 
were available for the comparison t(8; 21)+ vs. t(8; 21)−. In a comparison, in which one of the two groups is that 
small, it is unlikely to obtain significant results even when the actual effects are strong. Also, for the comparison 
RUNX1+ vs. RUNX1− we had much less observations available than in the main analysis – in the validation 
cohort there were less than half as many observations with RUNX1+ and RUNX1−, respectively, than there were 
available in the main analysis for validation using AMLCG Cohort 1.
Beyond statistical significance – which highly depends on sample size, the magnitudes of the effects observed 
in the validation cohort are of crucial importance. Supplementary Fig. S7 shows the (standardized) RPKM val-
ues of the three genes, separated by whether RUNX1 mutations, fusions, or neither of these two are present in 
the samples (cf. also Fig. 6 for the corresponding values obtained for the data used in the main analysis). For 
each gene, the RPKM values differ strongly between these groups, where the differences between patients with 
mutations and fusions are particularly strong. Supplementary Fig. S8 shows for all patients without mutations or 
fusions from the validation cohort, Kaplan Meier curves comparing the survival outcomes of patients with high 
and patients with low RPKM values with respect to the three considered genes. These curves give a very similar 
picture as those obtained in the main analysis (cf. Supplementary Fig. S6): The three genes seem to influence 
survival also for patients without RUNX1 mutations or the t(8; 21) fusion. Moreover, higher RPKM values are 
associated with higher risks for each of the three genes.
To summarize: The sample sizes available in the validation cohort were much smaller than those available in 
the main analysis, in particular for the comparison t(8; 21)+ vs. t(8; 21)−, which leads to a lower power of the 
tests on mediation activity. Against this background, a (strictly) significant result was only obtained for KIAA0125 
with respect to the comparison RUNX1+ vs. RUNX1−. However, the descriptive analysis (Supplementary Figs S7 
and S8) of the validation cohort was indicative that these three genes indeed show mediation activity with respect 
to the survival differences observed between patients with RUNX1 mutations and fusions, respectively.
Discussion
Using mediation analysis we identified three genes that may help to explain the strong differences in outcome 
between AML patients with RUNX1 mutations and RUNX1/RUNX1T1 fusions. We aimed to validate our results 
in a smaller, independent validation cohort. In this analysis, one of the three genes, KIAA0125, was again sig-
nificant with respect to playing a mediating role in the influence RUNX1/RUNX1T1 fusions have on survival. 
While the other investigated influences associated with the three genes were not significant, we note that the 
observed effects were almost without exception as strong as in the main analysis. Thus, the lack of significant 
results obtained using the independent validation cohort may well be due to the small sample sizes available for 
this analysis.
In the main analysis we used one data set for pre-selecting promising candidate genes and one data set for 
testing the candidate genes from the pre-selection. For testing the candidate genes in the second step, we used 
the largest data set AMLC Cohort 1, because for the pre-selection (i.e., the first step) less statistical power was 
required, since in this step we merely filtered out genes that showed little indications for mediation activity. As a 
sensitivity analysis, it would have been possible to change the roles of the data sets used for the pre-selection and 
the validation, in order to verify, whether we would have identified the same genes if the roles of pre-selection 
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Figure 8. Survival differences between patients with high and low gene expression values. Each subplot shows 
the Kaplan Meier curves of patients with expression values higher/lower than the median expression value for 
one of the three genes (panel a: CD109, panel b: KIAA0125, panel c: HOPX) selected from both the RUNX1+ 
vs. RUNX1− comparison and the t(8; 21)+ vs. t(8; 21)− comparison. In each case, the data set AMLCG Cohort 
1 was used. Censorings are indicated as plus signs. The p values are the results of log-rank tests used to test for 
survival differences between the two groups associated with the respective Kaplan Meier curves.
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It is known that variable selection using high-dimensional data is highly dependent on the data used for the 
selection26,27. Moreover, the variables identified in such analyses are usually only a small subset of the actually 
relevant variables. Thus, we expect that we would have obtained different selected genes in the sensitivity analysis 
described above, where both sets (this new one and the one we identified in our analysis) contain relevant genes 
but do not fully overlap. However, reporting all these genes as significant would lead to accumulating false pos-
itive results (the global significance level is 0.05 for one repetition of the analysis only - it inflates when several 
repetitions are performed).
The transcription factor RUNX1 plays a crucial role in the hematopoietic system and is essential for differen-
tiation28. Alterations of RUNX1 (RUNX1 mutations and RUNX1/RUNX1T1 fusion) are observed in about 20% 
of AML patients and therefore belong to the most common genetic abnormalities associated with AML23. This 
frequency and the fact that RUNX1 mutations and the RUNX1/RUNX1T1 fusion are almost never observed in 
the same patient suggest that alterations of RUNX1 play an important role in leukemogenesis and that RUNX1/
RUNX1T1 fusion and RUNX1 mutations are competing events. In addition, t(8; 21) positive leukemias have a spe-
cific set of cooperating mutations (e.g. tyrosine kinase and RAS pathway activations) which differ from RUNX1 
mutated leukemias that show a different set of cooperating mutations23,29. Furthermore, patients harboring a 
RUNX1 fusion are usually of younger age than patients having RUNX1 mutations19,30. We were interested in the 
question, whether, despite these differences, there is a common ground that connects both types of leukemia 
which dramatically differ in their clinical behavior. Our analysis aimed to elucidate these relationships by the 
analysis of gene expression data from 1514 AML patients. By applying a mediation analysis and performing val-
idation analyses of our results in different independent data sets that used different techniques to measure gene 
expression, we identified three genes that show strong indications for association with the observed difference in 
prognosis in the considered data, suggesting a common mechanism and connecting both types of RUNX1 altera-
tions. Higher expression of each of these genes was associated with inferior prognosis in intensively treated AML 
patients. Interestingly, we could demonstrate that these three genes show predictive potential even in patients 
without RUNX1 mutations or RUNX1 fusions. Hence, CD109, KIAA0125, and HOPX seem to be involved in 
or are surrogates of cellular processes that reflect a more aggressive disease independent of the fact that their 
expression levels might be directly affected by RUNX1 alterations in AML. In subsequent analyses we were able 
to identify indications for specific cellular processes like lipid localization and phospholipid transporter activity 
associated with this difference.
One of the identified genes, namely HOPX, has been shown to be a direct target of the RUNX1 transcrip-
tion factor24. It is therefore tempting to speculate that expression levels of this gene are affected by the mutated 
RUNX1 protein or the RUNX1 fusion protein. The regulation of the other candidates seems to be more complex. 
Interestingly, CD109 and KIAA0125 (FAM30A) were previously identified by other groups to have prognostic 
relevance in cancer. High expression of CD109 is associated with unfavorable prognosis in diffuse large B-cell 
lymphoma (DLBCL), soft tissue sarcoma and several other cancers31–33. CD109 codes a glycosyl phosphatidy-
linositol (GPI)-linked cell surface glycoprotein and regulates TGF-β signaling32,33. Since CD109 is also expressed 
on platelets and is associated with alloimmune thrombocytopenia, it may be a potential therapeutic target34. The 
gene KIAA0125, a long non-coding RNA (lnc RNA), was shown to be involved in migration and invasion in 
gallbladder cancer35.
Mediation analysis is an analysis technique for testing whether variables of interest are mediators in the 
observed influence of certain, usually binary variables on the outcome. In our analysis the potential mediators 
were the gene expression variables, the influencing variables were the mutation and the fusion (presence vs. 
absence) and the outcome was overall survival. In this context, mediation analysis can be viewed as an explor-
ative statistical approach towards large-scale systems biology. Due to the generality of mediation analysis, such 
approaches may be applied in any settings in the context of gene expression analysis, in which the interest lies 
in identifying genes that play a role in the observed influence of exploratory (binary) variables on the outcome. 
Mediation analysis is not restricted to survival data: There exist corresponding methods to that of Lange and 
Hansen16 for other outcome types as well.
As stated in the introduction, only a single publication that uses mediation analysis in gene expression anal-
ysis seems to exist. In this regard our work is pioneering, which is why we placed a great focus on describing the 
methodology we used in performing our analyses. Mediation analysis offers great potential to address important, 
still unanswered questions in the area of hematologic malignancies (and beyond). Researchers who have access to 
respective data sets may use our analysis design as a template for their own analyses. In doing so, they may obtain 
new insights in hematologic malignancies that are beyond the scope of traditional analysis approaches such as 
differential expression analysis using limma. We leave it to the interested reader to choose research questions that 
can be tackled using mediation analysis.
Note, however, that mediation analysis does not per se prove the causal character of relationships between 
exposure and mediator and between mediator and outcome adjusted for the influence of the exposure on out-
come. Mediation analysis is based on regression models. Whether the effects identified in these regression models 
reflect causal mechanisms, and if so whether these causal effects are direct, should be further investigated. For 
example, the expression of a gene might itself not be a causal factor influencing survival, but can instead be asso-
ciated with survival because it is associated with a causal factor. Mediation analysis cannot clarify such issues. It 
should thus be seen as an exploratory approach suggesting potential candidates for causal relationships.
Mediation analysis methods with high-dimensional molecular data, as used in our study, are still in their 
infancy from a statistical point of view. In the future, methodological developments may improve its perfor-
mance, for example with respect to the multiple testing procedures or to the simultaneous consideration of a large 
number of candidate biomarkers within a multivariable regression modeling framework. For the special case of 
a metric outcome variable, such a multivariable method has been published recently36. However, multivariable 
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mediator methods for survival outcomes still have to be developed. Methodological comparison studies are also 
needed to systematically assess mediation analyses approaches.
In summary, our analysis identified three gene expression markers that might help in explaining the observed 
prognostic difference between patients with RUNX1 mutations and the RUNX1/RUNX1T1 fusion. The expression 
levels of these genes exhibit prognostic potential also in patients without alterations of RUNX1 and point towards 
an oncogenic cooperative network. Further research is required to elucidate the specific role of these genes in 
AML.
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